Cyclomics
AI-powered diagnostic solutions
Earlier detection
Better outcomes
About us
At Cyclomics, our story begins with a clear mission: to revolutionize cancer diagnostics through innovation in molecular biology and sequencing.
Founded in the Netherlands, we are a biotechnology company specializing in advanced molecular diagnostics and DNA sequencing technologies.​​
Solutions
Our team of scientists and engineers has developed groundbreaking solutions such as CySeq®, our flagship consensus sequencing and liquid biopsy platform, and Epinn®, an AI-driven framework for rapid tumor classification. Together, these technologies empower clinicians and researchers to detect cancer earlier, monitor disease progression, and guide treatment decisions with greater precision and speed.​
Epinn®
Rapid tumour classification to assist the pathologist during diagnosis. Epinn® combines methylation sequencing with machine learning to classify tumour types quickly and accurately, shortening the timeline from 1 week to <90 minutes
CySeq®
CySeq® is a cutting-edge liquid biopsy and consensus sequencing platform, which enables highly sensitive detection of genetic mutations and cancer biomarkers from blood samples. And enables most comprehensive fragmentomics analysis on the market.